Cargando…
An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645265/ http://dx.doi.org/10.1186/2051-1426-3-S2-P169 |
| _version_ | 1782400795955691520 |
|---|---|
| author | Ribrag, Vincent Armand, Phillippe Kuruvilla, John Michot, Jean-Marie Moskowitz, Craig H Marinello, Patricia Snyder, Ellen Balakumaran, Arun Shipp, Margaret A Zinzani, Pier Luigi |
| author_facet | Ribrag, Vincent Armand, Phillippe Kuruvilla, John Michot, Jean-Marie Moskowitz, Craig H Marinello, Patricia Snyder, Ellen Balakumaran, Arun Shipp, Margaret A Zinzani, Pier Luigi |
| author_sort | Ribrag, Vincent |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645265 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46452652015-11-20 An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 Ribrag, Vincent Armand, Phillippe Kuruvilla, John Michot, Jean-Marie Moskowitz, Craig H Marinello, Patricia Snyder, Ellen Balakumaran, Arun Shipp, Margaret A Zinzani, Pier Luigi J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645265/ http://dx.doi.org/10.1186/2051-1426-3-S2-P169 Text en Copyright © 2015 Ribrag et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Ribrag, Vincent Armand, Phillippe Kuruvilla, John Michot, Jean-Marie Moskowitz, Craig H Marinello, Patricia Snyder, Ellen Balakumaran, Arun Shipp, Margaret A Zinzani, Pier Luigi An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 |
| title | An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 |
| title_full | An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 |
| title_fullStr | An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 |
| title_full_unstemmed | An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 |
| title_short | An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013 |
| title_sort | open-label, multicohort phase ib trial of pembrolizumab (mk-3475) for advanced hematologic malignancies: keynote-013 |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645265/ http://dx.doi.org/10.1186/2051-1426-3-S2-P169 |
| work_keys_str_mv | AT ribragvincent anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT armandphillippe anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT kuruvillajohn anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT michotjeanmarie anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT moskowitzcraigh anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT marinellopatricia anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT snyderellen anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT balakumaranarun anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT shippmargareta anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT zinzanipierluigi anopenlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT ribragvincent openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT armandphillippe openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT kuruvillajohn openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT michotjeanmarie openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT moskowitzcraigh openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT marinellopatricia openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT snyderellen openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT balakumaranarun openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT shippmargareta openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 AT zinzanipierluigi openlabelmulticohortphaseibtrialofpembrolizumabmk3475foradvancedhematologicmalignancieskeynote013 |